Avalo Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:AVTX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -40.54 M-70.89 M-26.75 M-30.68 M-49.06 M-51.46 M -59.69 M Cash from investing activities 11.13 M-113 K-95 K-133 K356 K-81.72 M -56.22 M Cash from financing activities 44.78 M106.76 M-14.7 M25.04 M175.85 M14.59 M 15.99 M Free cash flow -40.54 M-70.89 M-26.75 M-30.68 M-49.06 M-51.46 M -59.69 M

News

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Top Healthcare Stocks for This Year According to BTIG

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Avalo Therapeutics (NASDAQ:AVTX)

Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating

Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy

Avalo Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of trial data

This Valvoline Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Avalo Therapeutics (NASDAQ:AVTX), Lexeo Therapeutics (NASDAQ:LXEO)

Mizuho initiates Avalo Therapeutics stock with Outperform rating on HS drug potential

Avalo Therapeutics expands leadership with two senior appointments

Avalo Therapeutics appoints former Longboard CEO Kevin Lind to board

H.C. Wainwright raises Avalo Therapeutics stock price target to $25 on IL-1 pathway validation